Abstract
Encouraged by remarkable successes in preventing infectious diseases and by the well-established potential of the immune system for controlling tumor growth, active therapeutic immunization approaches hold great promise for treating malignant tumors. In recent years, engineered recombinant viral vectors have been carefully examined as genetic-immunization vehicles and have been demonstrated to induce potent T-cell-mediated immune responses that can control tumor growth. Very recent efforts suggest that lentivectors possess important advantages over other candidate recombinant viral vectors for genetic immunization. Here, we review the development of recombinant lentivectors and the characteristics of T-cell immune responses elicited by lentivector immunization, including the mechanism of T-cell priming with a focus on the role of skin dendritic cells and potential applications for tumor immunotherapy.
Original language | English (US) |
---|---|
Pages (from-to) | 913-924 |
Number of pages | 12 |
Journal | Expert Review of Vaccines |
Volume | 6 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2007 |
Keywords
- Dendritic cell subsets
- Gene delivery
- Genetic immunization
- Lentivector (lentiviral vector)
- Tumor immunotherapy
ASJC Scopus subject areas
- Immunology
- Molecular Medicine
- Pharmacology
- Drug Discovery